Lee Dahae, Kang Ki Sung, Yu Jae Sik, Woo Jung-Yoon, Hwang Gwi Seo, Eom Dae-Woon, Baek Seung-Hoon, Lee Hye Lim, Kim Ki Hyun, Yamabe Noriko
School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
College of Korean Medicine, Gachon University, Seongnam, Republic of Korea.
J Ginseng Res. 2017 Jul;41(3):284-289. doi: 10.1016/j.jgr.2016.05.002. Epub 2016 May 24.
Compound FK506 is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and inflammatory response mediated by FK506 limit its usefulness. In this study, the protective effect of Korean Red Ginseng (KRG) against FK506-induced damage in LLC-PK1 pig kidney epithelial cells was investigated.
LLC-PK1 cells were exposed to FK506 with KRG and cell viability was measured. Western blotting and RT-PCR analyses evaluated protein expression of MAPKs, caspase-3, and KIM-1. TLR-4 gene expression was assessed. Caspase-3 activities were also determined. The number of apoptotic cells was measured using an image-based cytometric assay.
The reduction in LLC-PK1 cell viability by 60μM FK506 was recovered by KRG cotreatment in a dose-dependent manner. The phosphorylation of p38, p44/42 MAPKs (ERK), KIM-1, cleaved caspase-3, and TLR-4 mRNA expression was increased markedly in LLC-PK1 cells treated with 60μM FK506. However, with the exception of p-ERK, elevated levels of p-p38, KIM-1, cleaved caspase-3, and TLR-4 mRNA expression were significantly decreased after cotreatment with KRG. Activity level of caspase-3 was also attenuated by KRG cotreatment. Moreover, image-based cytometric assay showed that apoptotic cell death was increased by 60μM FK506 treatment, whereas it was decreased after cotreatment with KRG.
Taken together, these results suggest that the molecular mechanism of KRG in the FK506-induced nephrotoxicity may lead to the development of an adjuvant for the inhibition of adverse effect FK506 in the kidney.
复方FK506是一种免疫抑制剂,常用于预防移植后实体器官的排斥反应。然而,由FK506介导的细胞凋亡和炎症反应所导致的肾毒性限制了其应用。在本研究中,研究了高丽参(KRG)对FK506诱导的LLC-PK1猪肾上皮细胞损伤的保护作用。
将LLC-PK1细胞与KRG共同暴露于FK506中,并测定细胞活力。蛋白质印迹法和逆转录-聚合酶链反应(RT-PCR)分析评估丝裂原活化蛋白激酶(MAPKs)、半胱天冬酶-3(caspase-3)和肾损伤分子-1(KIM-1)的蛋白表达。评估Toll样受体4(TLR-4)基因表达。还测定了caspase-3活性。使用基于图像的细胞计数法测量凋亡细胞数量。
60μM FK506导致的LLC-PK1细胞活力降低通过与KRG共同处理以剂量依赖的方式得以恢复。在用60μM FK506处理的LLC-PK细胞中,p38、p44/42 MAPKs(细胞外信号调节激酶,ERK)、KIM-1、裂解的caspase-3的磷酸化以及TLR-4 mRNA表达显著增加。然而,除了p-ERK外,在用KRG共同处理后,p-p38、KIM-1、裂解的caspase-3的升高水平以及TLR-4 mRNA表达均显著降低。KRG共同处理也减弱了caspase-3的活性水平。此外,基于图像的细胞计数法显示,60μM FK506处理增加了凋亡细胞死亡,而与KRG共同处理后则减少。
综上所述,这些结果表明KRG在FK506诱导的肾毒性中的分子机制可能导致开发一种用于抑制FK506在肾脏中不良反应的佐剂。